Nanotechnology-based diagnosis of COPD

Chronic obstructive pulmonary disease (COPD), which includes emphysema and bronchitis, induces airflow limitation and shortness of breath. Early diagnosis slows disease progression, enhances treatment, decreases healthcare expenditure, and sustains quality of life. Classic detection techniques like spirometry, chest X-rays, CT scans, cytokine tests, pulse oximetry, and exhaled nitric oxide tests can be expensive and fail to detect early instances. Nanotechnology improves COPD detection by providing sensitive, noninvasive procedures. Nanomaterials such as nanoparticle-labeled immunosensors, quantum dots, and carbon nanotubes allow for specific detection of biomarkers, including inflammatory cytokines and markers of oxidative stress. Such technologies enable noninvasive testing, such as exhaled breath analysis and enhanced imaging methods. Nanotechnology also helps with quick point-of-care testing, which enables doctors to diagnose COPD early and tailor treatment to each patient, leading to better COPD management and patient outcomes. Future opportunities for COPD diagnosis include additional research to create effective, low-cost medical devices through nanotechnology. This includes maximizing nanomaterials' sensitivity, making devices more portable, ensuring they are biocompatible, and overcoming regulatory issues for widespread use in the practical world.